Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4

BACKGROUND: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. However, the efficacy of FOLFOX4 for HCC patients is st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asian Pac J Cancer Prev
Hauptverfasser: Qin, Shukui, Zhang, Xinji, Guo, Wei, Feng, Jian, Zhang, Tianyi, Men, Lichuang, He, Jia
Format: Artigo
Sprache:Inglês
Veröffentlicht: West Asia Organization for Cancer Prevention 2017
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5555527/
https://ncbi.nlm.nih.gov/pubmed/28610406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2017.18.5.1225
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge